NYSE Places Provectus Listing Status Under Review
My Blog
NYSE Places Provectus Listing Status Under Review
By: Adam Feuerstein
| 05/27/14 - 09:48 AM EDT
Provectus Biopharmaceuticals (PVCT) is having a bad Tuesday. The New York Stock Exchange has placed Provectus' listing status under review, following Friday's PV-10 Breakthrough Therapy Designation debacle. Read more [...]